NCT03928288View on ClinicalTrials.gov

Cabergoline for the Treatment of Chronic Pain Due to Endometriosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Endometriosis
Interventions
DRUG

Cabergoline 0.5 MG

Medication

DRUG

Placebo - Cap

Placebo capsule

Trial Locations (6)

19107

Thomas Jefferson University Hospital, Philadelphia

80045

Childrens Hospital Colorado, Aurora

94305

Standford University, Palo Alto

02115

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

Children's Hospital Boston, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Thomas Jefferson University

OTHER

collaborator

Stanford University

OTHER

collaborator

Children's Hospital Colorado

OTHER

collaborator

Brigham and Women's Hospital

OTHER

lead

Boston Children's Hospital

OTHER